Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal InseminationATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology. The FemSperm Analysis ...

Core Insights - Femasys Inc. has launched the FemSperm Insemination Prep Kit, enhancing the sperm preparation process for FemaSeed Intratubal Insemination, aimed at increasing revenue growth through gynecologist activation [1][2][3] - The introduction of this kit is a significant step in Femasys' strategy to penetrate the underserved fertility market, providing a streamlined in-office solution for gynecologists [2][3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4] - The company’s fertility portfolio includes FemaSeed, which is positioned as a first-step infertility treatment, and FemVue, a diagnostic tool for fallopian tube assessment [4] Product Details - The FemSperm Insemination Prep Kit allows gynecologists to perform sperm preparation and offer FemaSeed Intratubal Insemination directly in their practices, addressing the needs of an estimated 10 million U.S. women facing infertility [3] - FemaSeed has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count, making it a safer and cost-effective alternative to IVF [3][4] Market Strategy - The commercialization of FemBloc, a non-surgical permanent birth control method, has received regulatory approvals in Europe, the UK, and New Zealand, with plans for strategic partnerships to enhance market presence [5] - Femasys aims to broaden patient access to fertility treatments and strengthen its long-term revenue growth strategy by positioning FemaSeed as a first-step treatment before IVF [2][3]

Core Insights - Femasys Inc. has launched the FemSperm Setup Kit, the first product in a new line aimed at enabling gynecologists to offer FemaSeed Intratubal Insemination, thereby expanding access to fertility treatments and driving revenue growth [1][2] - The FemSperm Setup Kit includes a pre-configured centrifuge for optimal sperm preparation, facilitating a streamlined in-office solution for gynecologists [1][2] - FemaSeed is positioned as a first-step fertility treatment that enhances natural fertilization by delivering sperm directly to the fallopian tube, showing more than double the pregnancy rates compared to traditional intrauterine insemination (IUI) in cases of low male sperm count [2][3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company is actively commercializing its lead product innovations, including FemaSeed and FemVue, in the U.S. and key international markets [3] - Femasys' FemBloc product, a non-surgical permanent birth control solution, received regulatory approval in Europe and the UK in mid-2025, with commercialization planned through strategic partnerships [4]

Core Viewpoint - Femasys Inc. has made significant progress in securing regulatory approvals and expanding its commercialization efforts for its fertility portfolio, including the FemBloc and FemaSeed products, which aim to enhance accessibility and cost-effectiveness for women globally [3][4][19]. Group 1: Regulatory Approvals and Partnerships - The European approval of the FemBloc System marks the first global regulatory endorsement for Femasys's non-surgical permanent birth control solution, with initial commercial availability in Spain [3][7]. - Regulatory approvals for FemaSeed in Australia and New Zealand have been secured, providing opportunities for revenue growth and expansion [4][7]. - A new partnership with Carolinas Fertility Institute aims to enhance patient support and access to FemaSeed across its eight locations [4][7]. Group 2: Financial Performance - Sales for the second quarter of 2025 increased by $187,784, or 84.8%, reaching $409,268 compared to $221,484 in the same period of 2024, driven by FemaSeed and FemVue sales [8][16]. - Research and development expenses decreased by $561,446, or 28.4%, to $1,414,429 for the second quarter of 2025, primarily due to commercialization efforts and reduced clinical costs [8][16]. - The net loss for the second quarter of 2025 was $4,585,922, or ($0.16) per share, compared to a net loss of $4,684,574, or ($0.21) per share, for the same period in 2024 [8][17]. Group 3: Product Innovations - Femasys's fertility portfolio includes FemaSeed, which is over twice as effective as traditional intrauterine insemination (IUI) and has a comparable safety profile [18]. - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, with full regulatory approval in Europe, and aims to provide a safer and more cost-effective solution [19]. - The FemChec diagnostic product complements FemBloc by providing an ultrasound-based test to confirm procedural success [19].